The U.S. FDA approved Imbruvica for the treatment of relapsed or refractory marginal zone lymphoma, a rare form of blood cancer.

The drug, which is jointly developed and commercialized by AbbVie Inc.'s Pharmacyclics LLC and Johnson & Johnson's Janssen Biotech Inc., is already approved for patients with mantle cell lymphoma, chronic lymphocytic leukemia and Waldenstrom's macroglobulinemia blood cancers.